World Library  
Flag as Inappropriate
Email this Article

Cross listing

Article Id: WHEBN0007959932
Reproduction Date:

Title: Cross listing  
Author: World Heritage Encyclopedia
Language: English
Subject: Stock market, Given Imaging, Global depository receipt, Celanese, Midpoint (company)
Collection: Securities (Finance), Stock Market
Publisher: World Heritage Encyclopedia

Cross listing

Cross listing of one company on multiple exchanges should not be confused with dual listed companies, where two distinct companies - with separate stocks listed on different exchanges - function as one company.

Cross listing of shares is when a firm lists its equity shares on one or more foreign stock exchange in addition to its domestic exchange. This concept is distinctly different than examples such as: American Depositary Receipt (ADR), European Depositary Receipt (EDR), International Depository Receipt (IDR) and Global Registered Shares (GRS).

ADR's, GDR's and the like are a mechanism to repackage a security primarily listed on an Exchange (such as Frankfurt) to enable it to be purchased by an investor outside of that market (such as within the US on the NYSE). This is a distinct instrument, as not all the rights may come with the ADR (GDR,EDR,IDR, etc.), and the ADR is subject to the fluctuations of the underlying currency. The original issue (on Frankfurt) would be priced in EUR, while the ADR is priced in USD. In most cases, the ADR is convertible back into the original instrument (but needs to go through a process of conversion). The ADR (GDR,IDR,EDR, etc.) also receives a different ISIN number, recognizing that it is not the same fungible instrument as the underlying stock.

However, many companies cross-list, where the stock is technically fungible between exchanges. Royal Dutch Shell, IBM, and Seimens are all examples where the same issue is traded in multiple markets ("multi-listed"). However, in Frankfurt and Paris, they are traded in EUR, London in GBP and on NYSE in USD. Prices are subject to local market conditions, as well as FX fluctuations and are not kept in perfect parity between markets. They tend to be more liquid than ADRs, GDRs and those types of conventions. While 'technically' fungible, these separate primary listings (they would all be considered 'primary' listings) are subject to re-registration which creates significant settlement risk if an investor wants to buy on one exchange and sell in another (especially where the currencies differ).

This primary listing activity should be noted as distinctly different than secondary listings, such as listings from the NYSE carried on regional exchanges such as Boston, Philadelphia or others within the same marketplace, or on MTF's (Multilateral trading facility) such as Chi-X or BATS.

Also, this is distinct from being 'admitted for trading' where a foreign share is accessible in a different market through an exchange convention, and not actually registered within that different market.

Generally such a company's primary listing is on a stock exchange in its country of incorporation, and its secondary listing(s) is/are on an exchange in another country. Cross-listing is especially common for companies that started out in a small market but grew into a larger market. For example, numerous large non-U.S. companies are listed on the New York Stock Exchange or NASDAQ as well as on their respective national exchanges such as Enbridge, BlackBerry Ltd, Statoil, Ericsson, Nokia, Toyota and Sony.


  • Cross or Multi-listing v Depository Receipts 1
  • Admitted for Trading v Cross/Multi-listing 2
  • Motivations for cross-listing 3
  • Costs of cross-listing 4
  • What do managers say? 5
  • Do cross-listings create value? 6
  • See also 7
  • References 8
  • External links 9

Cross or Multi-listing v Depository Receipts

Depository Receipts are instruments derived from another underlying instrument while Multi-listed instruments represent the actual stock of a company. Depository Receipts are convertible back to ordinary shares, following a process dependent upon the sponsoring facility that created the instrument. Ownership of a Depository Receipt does not convey the same rights as a direct holder of equity shares until the Receipt is surrendered and converted into an actual equity share holding.

Multi listed or cross-listed shares, by contrast, are technically the same financial instrument. Fungibility is a concern across markets. For example, shares of IBM cannot be purchased on NYSE and sold, same-day, on the London Stock Exchange, even though IBM is cross listed in both markets. There is a re-registration process that must occur to move the number of outstanding shares from one jurisdiction to the other. This is primarily due to market inefficiencies and structures required to maintain the integrity of registered shares within specific jurisdictions (typically regulatory driven).

Admitted for Trading v Cross/Multi-listing

Shares traded in a true cross listing / multi listed scenario are processed, matched and settled via the market mechanisms specific to the local exchange. In this regard, even though shares of IBM bought on NYSE and shares of IBM purchased on LSE are technically the same instrument, those purchase on NYSE will settle via the mechanisms associated with NYSE and the DTCC in the United States. Those shares purchased on the LSE will settle via the mechanisms of the LSE and CREST in the United Kingdom.

Shares 'admitted for trading', such as IBM listed via ARCA in Frankfurt, will settle via DTCC. It is important to note that IBM is also cross-listed in Frankfurt, in which case, those transactions will settle via the local German market processes.

Motivations for cross-listing

The academic literature has identified a number of different arguments to cross-list abroad in addition to a listing on the domestic exchange. Roosenboom and Van Dijk (2009)[1] distinguish between the following motivations:

  • Market segmentation: The traditional argument for why firms seek a cross-listing is that they expect to benefit from a lower cost of capital that arises because their shares become more accessible to global investors whose access would otherwise be restricted because of international investment barriers.
  • Market liquidity: Cross-listings on deeper and more liquid equity markets could lead to an increase in the liquidity of the stock and a decrease in the cost of capital.
  • Information disclosure: Cross-listing on a foreign market can reduce the cost of capital through an improvement of the firm’s information environment. Firms can use a cross-listing on markets with stringent disclosure requirements to signal their quality to outside investors and to provide improved information to potential customers and suppliers (for example, by adopting US GAAP). Also, cross-listings tend to be associated with increased media attention, greater analyst coverage, better analysts’ forecast accuracy, and higher quality of accounting information.
  • Investor protection ("bonding"): Recently, there is a growing academic literature on the so-called "bonding" argument. According to this view, cross-listing in the United States acts as a bonding mechanism used by firms that are incorporated in a jurisdiction with poor investor protection and enforcement systems to commit themselves voluntarily to higher standards of corporate governance. In this way, firms attract investors who would otherwise be reluctant to invest.
  • Other motivations: Cross-listing may also be driven by product and labor market considerations (for example, to increase visibility with customers by broadening product identification), to facilitate foreign acquisitions, and to improve labor relations in foreign countries by introducing share and option plans for foreign employees.[2]

Costs of cross-listing

There are, however, also disadvantages in deciding to cross-list: increased pressure on executives due to closer public scrutiny; increased reporting and disclosure requirements; additional scrutiny by analysts in advanced market economies, and additional listing fees. Some financial media have argued that the implementation of the Sarbanes-Oxley act in the United States has made the NYSE less attractive for cross-listings, but recent academic research finds little evidence to support this, see Doidge, Karolyi, and Stulz (2007).[3]

What do managers say?

A questionnaire asking managers of international companies has shown that firms cross-list in the United States mainly because of specific U.S. business reasons (for instance U.S. acquisitions, U.S. business expansion and publicity), liquidity and status of U.S. capital markets, and industry specific reasons (listing of competitors, benefits of financial analysts). Meeting SEC disclosure requirements and preparing US-GAAP reconciliations were cited as the most important disadvantages. Officials of ADR companies without an official listing (Level I and Rule 144A ADR’s) perceived the expansion of the U.S. shareholder base as the principal benefit followed by specific U.S. business reasons. On the question of what deters them from an official US listing, they mentioned the time-consuming and expensive US-GAAP reconciliations as well as listing fees as the hardest impediments. Additional disclosure requirements were cited as less difficult to overcome.

Do cross-listings create value?

There is a vast academic literature on the impact of cross-listings on the value of the cross-listed firms. Most studies (for example, Miller, 1999) find that a cross-listing on a U.S. stock market by a non-U.S. firm is associated with a significantly positive stock price reaction in the home market.[4] This finding suggests that the stock market expects the cross-listing to have a positive impact on firm value. Doidge, Karolyi, and Stulz (2004)[5] show that companies with a cross-listing in the United States have a higher valuation than non-cross-listed corporations, especially for firms with high growth opportunities domiciled in countries with relatively weak investor protection. The premium they find is larger for companies listed at official US stock exchanges (Level II and III ADR programs) than for over-the-counter listings (Level I ADR program) and private placements (Rule 144A ADR’s). Doidge, Karolyi, and Stulz (2004) argue that a cross-listing in the United States reduces the extent to which controlling shareholders can engage in expropriation (through "bonding" to the high corporate governance standards in the United States) and thereby increases the firm’s ability to take advantage of growth opportunities. Recent research, see,[6] shows that the listing premium for crosslisting has evaporated, due to new U.S. regulations and competition from other exchanges. Some recent academic research finds that smaller foreign firms seeking cross listing venues may be opting for UK exchanges over U.S. exchanges due to the costs imposed by the Sarbanes-Oxley Act. On the other hand, larger firms seeking "bonding" benefits from a U.S. listing continue to seek a U.S. exchange listing.[7] There are also studies, however, such as Sarkissian and Schill (2009),[8] who argue that cross-listings do not create long-term valuation benefits.

The academic literature largely ignores cross-listings on non-U.S. exchanges. However, there are many cross-listings on exchanges in Europe and Asia. Even U.S. firms are cross-listed in other countries. In the 1950s there was a wave of cross-listings of U.S. firms in Belgium, in the 1960s in France, in the 1970s in the U.K., and in the 1980s in Japan (see Sarkissian and Schill, 2014).[9] Roosenboom and van Dijk (2009)[1] analyze 526 cross-listings from 44 different countries on 8 major stock exchanges and document significant stock price reactions of 1.3% on average for cross-listings on US exchanges, 1.1% on London Stock Exchange, 0.6% on exchanges in continental Europe, and 0.5% on Tokyo Stock Exchange. These findings suggest that cross-listings on Anglo-Saxon exchanges create more value than on other exchanges. They also highlight the incomplete understanding of why firms cross-list outside the UK and the United States, as many of the arguments discussed above (enhanced liquidity, improved disclosure, and bonding) do not apply. In this respect, Sarkissian and Schill (2014) show that cross-listing activity in a given host country coincides with the outperformance of host and proximate home country’s economies and financial markets, thus, highlighting the market timing component in cross-listing decisions.

See also


  1. ^ a b "The Market Reaction to Cross-Listings: Does the Destination Market Matter?". 
  2. ^ "Disclosure Practices of Foreign Companies Interacting with U.S. Markets". 
  3. ^ "Has New York Become Less Competitive in Global Markets? Evaluating Foreign Listing Choices over Time". 
  4. ^ Miller, Darius, 1999, The market reaction to international cross-listings: Evidence from depositary receipts. Journal of Financial Economics 51, 103-123.
  5. ^ "Why are Foreign Firms Listed in the U.S. Worth More?". 
  6. ^ "Crosslisting". 
  7. ^ "Regulation and Bonding: The Sarbanes-Oxley Act and the Flow of International Listings". 
  8. ^ "Are There Permanent Valuation Gains to Overseas Listings?". 
  9. ^ "Cross-Listing Waves". 
  • Lubberink and Huijgen, "Earnings Conservatism and Equity Raisings of Cross-listed Firms", unpublished working paper
  • Piotroski, Joseph D. and Srinivasan, Suraj, "Regulation and Bonding: The Sarbanes-Oxley Act and the Flow of International Listings", (January 2008). Available at SSRN
  • Khanna, Tarun, Palepu, Krishna and Srinivasan, Suraj, "Disclosure Practices of Foreign Companies Interacting with U.S. Markets" (December 2003). Harvard Business School Strategy Unit Working Paper No. 03-081 Available at SSRN or doi:10.2139/ssrn.408621

External links

  • Research and data on cross-listings on the website of Mathijs A. van Dijk.
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.